See more : Aclara Resources Inc. (ARA.TO) Income Statement Analysis – Financial Results
Complete financial analysis of Kymera Therapeutics, Inc. (KYMR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kymera Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Skytop Lodge Corporation (SKTPP) Income Statement Analysis – Financial Results
- Parfex SA (MLPFX.PA) Income Statement Analysis – Financial Results
- Graf Acquisition Corp. IV (GFOR-WT) Income Statement Analysis – Financial Results
- Crealogix Holding AG (0QK1.L) Income Statement Analysis – Financial Results
- Jiangsu Jingxue Insulation Technology Co.,Ltd. (301010.SZ) Income Statement Analysis – Financial Results
Kymera Therapeutics, Inc. (KYMR)
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 78.59M | 46.83M | 72.83M | 34.03M | 2.93M | 0.00 |
| Cost of Revenue | 189.08M | 2.98M | 2.40M | 62.11M | 825.00K | 205.00K |
| Gross Profit | -110.49M | 43.85M | 70.44M | -28.07M | 2.11M | -205.00K |
| Gross Profit Ratio | -140.59% | 93.64% | 96.71% | -82.48% | 71.88% | 0.00% |
| Research & Development | 189.08M | 164.25M | 137.02M | 62.11M | 37.16M | 17.68M |
| General & Administrative | 55.04M | 43.83M | 36.35M | 18.23M | 7.98M | 3.77M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 55.04M | 43.83M | 36.35M | 18.23M | 7.98M | 3.77M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 244.12M | 208.08M | 173.36M | 80.34M | 45.14M | 21.45M |
| Cost & Expenses | 244.12M | 208.08M | 173.36M | 80.34M | 45.14M | 21.45M |
| Interest Income | 18.76M | 6.62M | 488.00K | 826.00K | 1.01M | 0.00 |
| Interest Expense | 196.00K | 176.00K | 175.00K | 115.00K | 46.00K | 16.00K |
| Depreciation & Amortization | 3.57M | 2.98M | 2.40M | 1.76M | 825.00K | 205.00K |
| EBITDA | -143.20M | -151.66M | -97.65M | -43.72M | -40.38M | -21.25M |
| EBITDA Ratio | -182.21% | -330.23% | -137.36% | -133.63% | -1,376.11% | 0.00% |
| Operating Income | -165.53M | -161.26M | -100.53M | -46.30M | -42.21M | -21.45M |
| Operating Income Ratio | -210.62% | -344.37% | -138.03% | -136.05% | -1,438.48% | 0.00% |
| Total Other Income/Expenses | 18.57M | 6.45M | 313.00K | 711.00K | 959.00K | -16.00K |
| Income Before Tax | -146.96M | -154.81M | -100.22M | -45.59M | -41.25M | -21.47M |
| Income Before Tax Ratio | -186.99% | -330.60% | -137.60% | -133.96% | -1,405.79% | 0.00% |
| Income Tax Expense | 0.00 | -2.98M | -2.22M | -1.65M | 46.00K | 43.86K |
| Net Income | -146.96M | -151.83M | -98.00M | -43.95M | -41.29M | -21.47M |
| Net Income Ratio | -186.99% | -324.25% | -134.55% | -129.12% | -1,407.36% | 0.00% |
| EPS | -2.52 | -2.82 | -2.04 | -2.53 | -0.93 | -0.48 |
| EPS Diluted | -2.52 | -2.82 | -2.04 | -2.53 | -0.93 | -0.48 |
| Weighted Avg Shares Out | 58.37M | 53.93M | 47.99M | 17.35M | 44.53M | 44.53M |
| Weighted Avg Shares Out (Dil) | 58.37M | 53.93M | 47.99M | 17.35M | 44.53M | 44.53M |
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: Should You Buy?
Kymera Therapeutics, Inc. (KYMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
WATERTOWN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report fourth quarter and full year 2023 financial results...
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside...
Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs
IRAK4 oral degrader KT-474 (SAR444656) expected to complete enrollment in both Phase 2 HS and AD studies in fourth quarter of 2024, with topline data expected in first half of 2025
Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
WATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the closing of its upsized underwritten public offering...
Kymera Therapeutics Announces Pricing of $275 Million Public Offering
WATERTOWN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the pricing of its underwritten public offering of...
Kymera Therapeutics Announces Proposed Public Offering
WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that it has commenced an underwritten public offering...
R&D Day Highlights Kymera's Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases
Company's focus on advancing first-in-class oral degraders with biologics-like activity to address areas of significant patient need and market potential
Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024
WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced the Company will present at the 42nd Annual...
Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4
Company to provide update on its emerging pipeline of high-value immunology programs Company to provide update on its emerging pipeline of high-value immunology programs
Source: https://incomestatements.info
Category: Stock Reports